About Nutrinia

Nutrinia's Market Focus is Neonatal GI Rehabilitation and Maturation

Nutrinia is a neonatology company developing pharmaceuticals to treat rare conditions of the gastrointestinal tract. Our current products in development are oral formulations of insulin shown to enhance adaptation and rehabilitation of the gut in infants. We at Nutrinia live by the belief that science is best used to make life better for people, especially the most vulnerable populations. 

Management Team

Our qualified team members
Jill Thompson Quigley, Esq.
Interim CEO
Ms. Quigley is the interim Chief Executive Officer, General Counsel and Chief Administrative Officer of Nutrinia. Previously, Ms. Quigley served as legal counsel at several biotechnology companies, including as Senior Counsel at Shire plc, NPS Pharmaceuticals, Inc. where she served in several capacities including Interim General Counsel and a member of the Board of Directors for several foreign subsidiaries and was a key member of the NPS transaction team in it’s $5.2B acquisition by Shire, and Pharmasset, Inc., where she led the company’s regulatory compliance program and was integral in the negotiations that lead to the record-setting $11B acquisition by Gilead Sciences. Ms. Quigley began her career as an associate with the law firm of Dechert LLP, where she advised life science companies on a broad range of business and legal matters. She received an B.A. from American University and a J.D. with high honors from Rutgers School of Law.
Tal Atarot
Tal is an executive with over 18 years of experience in medicinal product development for biotechnology and pharmaceutical companies. Prior to joining Nutrinia, Tal served as COO and VP of Clinical and Regulatory Affairs for I2O Pharma, which specializes in switching injectable drugs to oral formulation. Tal was also COO and VP of Clinical and Regulatory Affairs for Vecta, developing pharmaceutical treatments for GI-tract diseases. He has been a regulatory affairs associate as well as R&D team member for TEVA Pharmaceuticals.
Tal received his B.Pharm magna cum laude from The School of Pharmacy at Hebrew University of Jerusalem, and M.Sc. in Bioinformatics at the interdisciplinary program of The Weizmann Institute of Science.
Jon Beauchamp
SVP European Operations
Dr Jon Beauchamp trained in medicine and practiced in the UK and Australia before joining the biotech industry in 2005. Prior to joining Nutrinia, Jon spent 9 years at Alexion where he brought therapy expertise as VP Global Medical Affairs Lead Nephrology, European leadership as VP EMEA Medical Affairs as well as commercial leading sales, marketing and diagnostics as Business Unit Lead for Soliris. Jon studied medicine in London.
Naim Shehadeh, MD
Dr. Shehadeh is a leading researcher in the field of juvenile diabetes. Driven by the vision of making a milk replacement formula as healthy as mother’s milk, Dr. Shehadeh progressed from his clinical studies of insulin concentration in human milk to a practical application for delivery of bioactive proteins in commercial infant formula. He is Director of Pediatrics A and the Pediatric Diabetes Unit at Meyer Children’s Hospital of Haifa at Rambam Medical Center. Prof. Shehadeh has received a number of research and innovation awards, including the Hershel Rich Technion Innovation Award and the Raymond and Miriam Klein Technion Research Award.
Raanan Shamir, MD
Medical Advisor
Raanan Shamir is currently the chairman of the Institute of Gastroenterology, Nutrition, and Liver Diseases at Schneider Children’s Medical Center of Israel, and is a professor of Pediatrics at the Sackler Faculty of Medicine at Tel Aviv University, Israel. Prof. Shamir received his MD degree from Hebrew University in Jerusalem, Israel, and trained in Pediatrics at the Beilinson Medical Center, in Petach-Tiqva, Israel.

Board of Directors

Anat Naschitz
Board Member
Anat Naschitz, Managing Director at OrbiMed, has over 19 years of international healthcare operational and investment experience. OrbiMed Advisors LLC is a leading healthcare investment firm, with approximately $12 billion in assets under management. OrbiMed invests globally out of five offices – New York, Tel Aviv, San Francisco, Shanghai and Mumbai – in private and public companies across stages, through a series of funds. OrbiMed Israel has $222 million in committed capital.
Gary Jacobs
Board Member
Mr. Gary Jacobs is the Founder and Managing Director of Jacobs Investment Company LLC (JIC).  JIC invests in many technological companies both in the US and Israel. Mr. Jacobs serves on numerous boards, including NGT3 technological incubator Nazareth. In the community, Mr. Jacobs is the Past President of the United Jewish Federation of San Diego County. In addition Mr. Jacobs serves as Chairman of the Board of Trustees of the Gary and Jerri-Ann Jacobs High Tech High, a charter high school. Gary and Jerri-Ann Jacobs are the founders of JITLI -International Teen Leadership Institute.
Aaron Davidson
Board Member
Mr. Davidson is Co-head and Managing Director of H.I.G. BioHealth Partners, where he focuses on investment opportunities in the life sciences sector. He began his career with Eli Lilly and Company, where he spent a decade in various management roles in the United States and Canada including business development, strategic planning, market research, and financial planning. Mr. Davidson earned his MBA from Harvard Business School and a bachelor’s degree from McGill University. Mr. Davidson currently serves on the boards of Cardeas Pharma, Forsight Vision5, HyperBranch Medical Technology and Intact Vascular. He represented H.I.G. as a board member in several successful companies including: Alder Biopharmaceuticals (public), Novadaq Technologies (public), Salmedix (acquired) and Gemin X Pharmaceuticals (acquired).
Eran Nadav, Ph.D.
Board Member
Dr. Nadav serves as Partner and Managing Director at TPG Biotech, the life science venture investment arm of the global private investment firm TPG. He joined TPG in 2007, to invest in pharmaceuticals and biotechnology across various geographies and stages of development. Prior to TPG, he served as Business Development Director at Eisai, where he evaluated and negotiated licensing and acquisition deals. Prior to that, Dr. Nadav worked for the Israeli office of JJDC, the venture capital subsidiary of Johnson & Johnson. Previously, Dr. Nadav worked for Neurim Pharmaceuticals Ltd. supporting the clinical development of Circadin®. He holds a Ph.D. in Biochemistry, M.Sc. magna cum laude, B.Sc. magna cum laude, and MBA from Tel Aviv University. Dr. Nadav is currently Chairman of the Board of Trevi Therapeutics, and board member at Collegium Pharmaceutical (Nasdaq: COLL), ShangPharma (a China based CRO), and NovaSom. He was the lead investor and Chairman of the Board of Ultragenyx Pharmaceutical (Nasdaq: RARE). His other past investments and board roles include JCR Pharmaceuticals (a Japanese biopharma company, TSE: 4552), MacroGenics (Nasdaq: MGNX), and Mey Eden.
Ran Nussbaum
Board Member
Ran is a managing partner and co-founder of The Pontifax Group. The fund is running more than 45 portfolio companies all around the globe. Prior to joining Pontifax, he was a partner at Israel’s largest business intelligence and strategic consulting firm. Ran’s work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. Ran serves as a board member on many of Pontifax’s portfolio companies, including Kite pharma, Keros (as chairman), Urogen Ltd, cCAM Biotherapeutics ,Eloxx Ltd., BioBlast, NovellusDX, and other bio-pharma companies. He also chaired OCON Medical, NasVax and ran Biomedix and Spearhead in the past.
Stephen Squinto, Ph.D.
Board Member
Stephen is a Venture Partner with OrbiMed who brings over 25 years of biotechnology industry experience. Dr. Squinto was a co-founder of Alexion Pharmaceuticals, Inc. and recently served as its Executive Vice President and Chief Global Operations Officer. Prior to 2013, he was Alexion’s Global Head of Research and Development. He is a recipient of numerous honors and awards from academic and professional organizations for his scientific work. Dr. Squinto received his B.A. in Chemistry and Ph.D. in Biochemistry and Biophysics from Loyola University of Chicago.


Wei Li, Ph.D.
Dr. Li is Managing Director of WuXi Healthcare Ventures II, with over 20 years of experience as a successful executive and entrepreneur in the biotech industry. Prior to joining WuXi Healthcare Ventures, Dr. Li focused his effort on healthcare and life science investment opportunities at Fidelity Biosciences, Fidelity Growth Partner Asia, and Baird Venture Partners. He also led drug discovery projects and technology licensing due diligence at Vertex Pharmaceuticals. During his scientific career, Wei authored numerous scientific publications in journals such as Science, Proceedings of the National Academy of Sciences, and the Journal of Biological Chemistry. Dr. Li received a B.S., with distinction, in Chemical Physics from University of Science and Technology of China, a Ph.D. in Biochemistry and Mammalian Genetics from Harvard University, and an MBA from the Kellogg School of Management at Northwestern University, where he was elected Beta Gamma Sigma, with a concentration in Finance, Accounting and Marketing.
Cayce Denton
Cayce Denton serves as Vice President at TPG Biotech, the life science venture investment arm of the global private investment firm TPG. Prior to joining TPG in 2010, Ms. Denton managed finance for the Nutropin and Lytics franchises at Genentech, and participated in a CFO Rotation Program. Previously, she was in Business Development at Novartis in Cambridge, where she helped execute an approximately $700 million partnership with Alnylam Pharmaceuticals, and worked in biotech venture capital at Atlas Venture and in investment banking at CSFB. Ms. Denton has an MBA from the Wharton School of the University of Pennsylvania, where she was awarded the F. H. Shields Fellowship and co-founded the Biotech Investment Group, and a B.S. from M.I.T. in Biology. Currently she sits on the board of directors of PatientSafe Solutions and Trevi Therapeutics.
Jorge Ramirez
Jorge Ramirez is a Vice President at H.I.G. BioHealth Partners, and previously was with ProQuest Investments. During his eight years at ProQuest, he was an observer or board member at several successful companies including: Eagle Pharmaceuticals (NASDAQ: EGRX), Mevion Medical Systems, Revision Optics, Orthocon (acquired by AbyRx), and MethylGene (now Mirati Pharmaceutics: NASDAQ: MRTX). He was also the General Manager of Neurology Products at Cyberkinetics Neurotechnology Systems, where he led the regulatory and clinical development teams for an epilepsy monitoring device and had P&L responsibility for Cyberkinetics’ research products. Previously, Mr. Ramirez was a management consultant at Monitor Company. Mr. Ramirez earned degrees in Neuroscience and Spanish literature from Amherst College, where he graduated magna cum laude. He earned an MBA from Harvard Business School, where he was a Pfizer Scholar and Social Enterprise Fellow.

Our Investors

We Have the Best Investors and Partners
Orbimed logo
Pontifax Logo Small
Wuxi Logo 1
HIG Capital
Maabarot Logo